Advanced Biomed Inc. Files 8-K Report
Ticker: ADVB · Form: 8-K · Filed: Sep 19, 2025 · CIK: 1941029
| Field | Detail |
|---|---|
| Company | Advanced Biomed INC. (ADVB) |
| Form Type | 8-K |
| Filed Date | Sep 19, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, financials
TL;DR
Advanced Biomed Inc. filed an 8-K on 9/19/25 for Reg FD and financials.
AI Summary
On September 19, 2025, Advanced Biomed Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and the submission of financial statements and exhibits. The company is incorporated in Nevada and its principal executive offices are located in Tainan City, Taiwan.
Why It Matters
This 8-K filing indicates that Advanced Biomed Inc. is providing updated regulatory disclosures and financial information to the SEC, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine regulatory disclosure and does not appear to contain any specific negative or positive material events.
Key Numbers
- 001-42548 — SEC File Number (Identifies the company's filing history with the SEC.)
- 87-2177170 — IRS Employer Identification Number (Unique identifier for tax purposes.)
Key Players & Entities
- Advanced Biomed Inc. (company) — Filer
- Nevada (jurisdiction) — State of Incorporation
- Tainan City, Taiwan (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to disclose information related to Regulation FD and to submit financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on September 19, 2025.
Where are Advanced Biomed Inc.'s principal executive offices located?
Advanced Biomed Inc.'s principal executive offices are located at No. 689-85 Xiaodong Road, Yongkang District, Tainan City, Taiwan.
In which state is Advanced Biomed Inc. incorporated?
Advanced Biomed Inc. is incorporated in Nevada.
What is the company's SEC file number?
The company's SEC file number is 001-42548.
Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-09-19 16:30:53
Filing Documents
- ea0258116-8k_advanced.htm (8-K) — 25KB
- ea025811601ex99-1_advanced.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 20KB
- 0001213900-25-089566.txt ( ) — 234KB
- advb-20250919.xsd (EX-101.SCH) — 3KB
- advb-20250919_lab.xml (EX-101.LAB) — 33KB
- advb-20250919_pre.xml (EX-101.PRE) — 22KB
- ea0258116-8k_advanced_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 19, 2025, the Company issued a press release regarding the launch of A+PerfusC – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery. A copy of the press release is attached as Exhibit 99.1 hereto. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference to this report in such filing.
01 Financial Statement and Exhibits
Item 9.01 Financial Statement and Exhibits. Exhibit No. Description 99.1* Press Release, dated September 19, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Furnished herewith. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Advanced Biomed Inc. Date: September 19, 2025 By: /s/ Yi Lu Yi Lu Chief Executive Officer 2